Literature DB >> 23017899

Differential subcellular targeting of recombinant human α₁-proteinase inhibitor influences yield, biological activity and in planta stability of the protein in transgenic tomato plants.

Shweta Jha1, Saurabh Agarwal, Indraneel Sanyal, G K Jain, D V Amla.   

Abstract

The response of protein accumulation site on yield, biological activity and in planta stability of therapeutic recombinant human proteinase inhibitor (α₁-PI) was analyzed via targeting to different subcellular locations, like endoplasmic reticulum (ER), apoplast, vacuole and cytosol in leaves of transgenic tomato plants. In situ localization of the recombinant α₁-PI protein in transgenic plant cells was monitored by immunohistochemical staining. Maximum accumulation of recombinant α₁-PI in T₀ and T₁ transgenic tomato plants was achieved from 1.5 to 3.2% of total soluble protein (TSP) by retention in ER lumen, followed by vacuole and apoplast, whereas cytosolic targeting resulted into degradation of the protein. The plant-derived recombinant α₁-PI showed biological activity for elastase inhibition, as monitored by residual porcine pancreatic elastase (PPE) activity assay and band-shift assay. Recombinant α₁-PI was purified from transgenic tomato plants with high yield, homogeneity and biological activity. Purified protein appeared as a single band of ∼48-50 kDa on SDS-PAGE with pI value ranging between 5.1 and 5.3. Results of mass spectrometry and optical spectroscopy of purified recombinant α₁-PI revealed the structural integrity of the recombinant protein comparable to native serum α₁-PI. Enzymatic deglycosylation and lectin-binding assays with the purified recombinant α₁-PI showed compartment-specific N-glycosylation of the protein targeted to ER, apoplast and vacuole. Conformational studies based on urea-induced denaturation and circular dichroism (CD) spectroscopy revealed relatively lower stability of the recombinant α₁-PI protein, compared to its serum counterpart. Pharmacokinetic evaluation of plant derived recombinant and human plasma-purified α₁-PI in rat, by intravenous route, revealed significantly faster plasma clearance and lower area under curve (AUC) of recombinant protein. Our data suggested significance of protein sorting sequences and feasibility to use transgenic plants for the production of stable, glycosylated and biologically active recombinant α₁-PI for further therapeutic applications.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017899     DOI: 10.1016/j.plantsci.2012.07.004

Source DB:  PubMed          Journal:  Plant Sci        ISSN: 0168-9452            Impact factor:   4.729


  5 in total

Review 1.  Vacuolar deposition of recombinant proteins in plant vegetative organs as a strategy to increase yields.

Authors:  Vanesa Soledad Marin Viegas; Carolina Gabriela Ocampo; Silvana Petruccelli
Journal:  Bioengineered       Date:  2016-09-20       Impact factor: 3.269

2.  Proteolytic and N-glycan processing of human α1-antitrypsin expressed in Nicotiana benthamiana.

Authors:  Alexandra Castilho; Markus Windwarder; Pia Gattinger; Lukas Mach; Richard Strasser; Friedrich Altmann; Herta Steinkellner
Journal:  Plant Physiol       Date:  2014-10-29       Impact factor: 8.340

3.  Production of pharmaceutical proteins in solanaceae food crops.

Authors:  Maria Manuela Rigano; Giorgio De Guzman; Amanda M Walmsley; Luigi Frusciante; Amalia Barone
Journal:  Int J Mol Sci       Date:  2013-01-29       Impact factor: 5.923

4.  Vacuolar targeting of recombinant antibodies in Nicotiana benthamiana.

Authors:  Carolina Gabriela Ocampo; Jorge Fabricio Lareu; Vanesa Soledad Marin Viegas; Silvina Mangano; Andreas Loos; Herta Steinkellner; Silvana Petruccelli
Journal:  Plant Biotechnol J       Date:  2016-06-14       Impact factor: 9.803

5.  Point Mutation of a Non-Elastase-Binding Site in Human α1-Antitrypsin Alters Its Anti-Inflammatory Properties.

Authors:  Yotam Lior; Mariana Zaretsky; David E Ochayon; Diana Lotysh; Boris M Baranovski; Ronen Schuster; Ofer Guttman; Amir Aharoni; Eli C Lewis
Journal:  Front Immunol       Date:  2018-05-01       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.